Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2CNS 2

Conditions

Melanoma 65Neoplasms 29Neoplasm Metastasis 11Thyroid Neoplasms 10Thyroid Carcinoma, Anaplastic 9Glioma 9Brain Neoplasms 9Multiple Myeloma 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Hematologic Neoplasms 6Thyroid Cancer, Papillary 4Skin Neoplasms 4Ameloblastoma 4Histiocytosis, Langerhans-Cell 3Glioblastoma 3Astrocytoma 3Rectal Neoplasms 2Prostatic Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Oligodendroglioma 2Neurofibroma, Plexiform 2Neurocytoma 2Neuroblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Lung Neoplasms 2Ganglioneuroma 2

Interventions

Cyclophosphamide 101Etoposide 60Carboplatin 55Vincristine 51Filgrastim 49Topotecan 44Temozolomide 44Melphalan 44Isotretinoin 44Doxorubicin 44Irinotecan 42Cisplatin 35Peripheral Blood Stem Cell Transplantation 31dinutuximab 29Radiotherapy 29Granulocyte Colony-Stimulating Factor 29sargramostim 283-Iodobenzylguanidine 27Granulocyte-Macrophage Colony-Stimulating Factor 25Busulfan 22Magnetic Resonance Spectroscopy 19aldesleukin 18Thiotepa 18fludarabine 17Interleukin-2 17humanized 3F8 anti-GD2 monoclonal antibody 16etoposide phosphate 16Ifosfamide 15naxitamab 14fludarabine phosphate 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neuroblastoma × dabrafenib × Clear all
NCT03975829 2026-05-11

Pediatric Long-Term Follow-up and Rollover Study

Novartis

Phase 4 Recruiting
165 enrolled
CNSMyeloid

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

NCT02124772 2021-07-14

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

Novartis

Phase 1/2 Completed
139 enrolled 42 charts 1 FDA
CNSMyeloid

Histiocytosis, Langerhans-Cell, Neoplasms, Neuroblastoma, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡